Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (OPSALIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01332656
Recruitment Status : Completed
First Posted : April 11, 2011
Last Update Posted : December 21, 2015
Information provided by (Responsible Party):

April 7, 2011
April 11, 2011
December 21, 2015
May 2011
July 2014   (Final data collection date for primary outcome measure)
Progression Free Survival (PFS) [ Time Frame: approximately 24 months ]
Same as current
Complete list of historical versions of study NCT01332656 on Archive Site
  • Overall Survival (OS) [ Time Frame: approximately 24 months ]
  • Objective Response Rate (RR) [ Time Frame: approximately 24 months ]
Same as current
Not Provided
Not Provided
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Primary Objective:

- To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin.

Secondary Objectives:

  • To compare the overall survival (OS) between the 2 treatment arms
  • To compare the objective response rate (RR) between the 2 treatment arms
Treatment will continue until disease progression or unacceptable toxicity or consent withdrawal. A minimum of 6 cycles of the combined therapies should be administered, unless progression occurs before or safety reasons cause the discontinuation of one or two drugs of the combination therapies. In case of no progression, it will be investigator's decision to continue or not the study treatment after 6 cycles according to his clinical practice.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Ovarian Cancer Recurrent
  • Drug: Ombrabulin (AVE8062)

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Drug: Placebo

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Drug: Paclitaxel

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Drug: Carboplatin

    Pharmaceutical form:solution

    Route of administration: intravenous

  • Experimental: Arm A
    Ombrabulin, Paclitaxel and Carboplatin
    • Drug: Ombrabulin (AVE8062)
    • Drug: Paclitaxel
    • Drug: Carboplatin
  • Placebo Comparator: Arm B
    Placebo, Paclitaxel and Carboplatin
    • Drug: Placebo
    • Drug: Paclitaxel
    • Drug: Carboplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2014
July 2014   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Signed informed consent.
  2. At least 18 years of age.
  3. Histological and/or cytological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma.
  4. Completion of maximum one previous line of chemotherapy containing a platinum agent. Neoadjuvant/adjuvant treatment that include a surgical procedure will be considered as one line if platinum-based.
  5. Documented sensitivity to a platinum based chemotherapy regimen. "Platinum-sensitivity" is defined by a relapse more than 6 months after last dose of platinum-based chemotherapy.
  6. Measurable progressive disease: Measurable disease (as defined by RECIST 1.1) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be at least 10mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >15 mm in short axis when measured by CT or MRI. In case of a single measurable lesion, this should not be previously irradiated.
  7. ECOG performance status ≤2
  8. Life expectancy more than 12 weeks

Exclusion criteria:

  1. History of uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis.
  2. History of another neoplasm. Adequately treated basal cell or squamous skin cancer, or in situ cervical cancer, or any other cancer from which the patient has been disease-free for >5 years are allowed.
  3. Participation in another clinical trial and any concurrent treatment with any investigational drug or anti-tumor therapy or radiotherapy within 21 days prior to randomization (or 28 days for those therapies with a schedule of administration every 4 weeks and except for nitrosoureas, mitomycin which may not be used up to 6 weeks prior to the first cycle provided that patients do not have residual signs of any toxicity). No wash-out is required for hormonotherapy which has to be discontinued before the first cycle.
  4. Any severe acute or chronic medical condition, which could impair the ability of the patient to participate in the study or interfere with interpretation of study results.
  5. Pregnancy or breast-feeding. Positive serum or urine pregnancy test prior to randomization.
  6. Patient with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and for at least 6 months after the completion of the study treatment. The definition of "effective method of contraception" will be based on the investigator's judgment. Effective method of contraception should also be adapted to local regulations.
  7. Inadequate organ function including: neutrophils <1.5 x 10^9/L; platelets <100 x 10^9/L; creatinine ≥ 1.5 ULN. If creatinine ≥ ULN, the calculated creatinine clearance should be ≥ 60 ml/min (as per Cockcroft Formula). Total bilirubin not within normal limit and ALT/AST/AP >2.5 times the upper normal limits of the institutional norms. An increase of AP up to grade 2 would be accepted only if this increase is related to the presence of bone metastases. Bone specific isoenzyme AP should be evaluated.
  8. Urine protein-creatinin ratio (UPCR) >1 (urinanalysis on morning spot urine) or proteinuria >500 mg/24h
  9. Pre-existing peripheral neuropathy > grade 1 according to the NCI CTCAE V.4.03
  10. Pre-existing hearing impairment > grade 1
  11. Known hypersensitivity due to taxanes and /or polysorbate 80 or any other compound/excipients of the study drug combination
  12. Discontinuation of previous treatment with paclitaxel and/or carboplatin for toxicity reason
  13. Other serious illness or medical conditions such as (but not restricted):

    • Active infection
    • Superior vena cava syndrome
    • Pericardial effusion requiring intervention (drainage)
  14. Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third-degree atrioventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 6 months still requiring anticoagulants.
  15. Cardiac Troponin at levels that exceed the normal ranges values defined by the laboratory
  16. Uncontrolled hypertension within 3 months prior to study treatment or patient with organ damage related to hypertension.
  17. Patient with LVEF value lower than institution inferior normal limit, evaluated by echocardiography or angiocardiography
  18. 12-lead ECG:

    • Infarction Q-wave,
    • ST segment depression or elevation ≥1 mm in at least 2 contiguous leads
    • QT/QTc-Time > 450ms

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   France,   Germany,   Italy,   Poland,   Russian Federation,   Spain,   Ukraine,   United States
2010-024631-16 ( EudraCT Number )
U1111-1118-5437 ( Other Identifier: UTN )
Not Provided
Not Provided
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP